SRNE News and Press, Sorrento Therapeutics Inc. From 10/09/20

Sorrento Therapeutics (SRNE) files for 996,803 share common stock offering by Selling Shareholder.See below company's ownership structure: For further details see: Sorrento holder to offer 997K shares

Sorrento Therapeutics ([[SRNE]] +7.4%) perks up, albeit on below-average volume, in reaction to its announcement that it has discovered a small molecule named Salicyn-30 that, it says, produced a 3-4 log (1,000x - 10,000x) reduction in SARS-CoV-2 viral load in a cell model.It identified Salic...

In preclinical studies, Salicyn-30, a small molecule, demonstrated potent in-vitro viral load reduction of 3-4 log in SARS-CoV-2 infection model in normal healthy VERO E6 cells. Salicyn-30 displays a novel mechanism of inhibition of SARS-CoV-2, with potential additive benefits whe...

Shares of the clinical-stage biotech Sorrento Therapeutics (NASDAQ: SRNE) gained a whopping 46.1% during the month of September, according to data provided by S&P Global Market Intelligence . For comparison, the iShares Nasdaq Biotechnology ETF gained only 1.8% last mont...

Scilex Holding, a majority-owned subsidiary of Sorrento Therapeutics (SRNE) announces Q/Q sales growth in ZTlido.Scilex expects Q3 2020 ZTlido net sales to grow 26% to ~$7.2M, compared to $5.7M in Q2-2020. Scilex’s SP-102 (SEMDEXA) is currently being evaluated in Phase 3 clinical ...

Preliminary Q3 2020 net sales of ZTlido ® of approximately $7.2 million, quarter-over-quarter growth of 26% compared to $5.7MM in Q2-2020 despite the continued impact of COVID-19 pandemic. The Phase 3 pivotal trial investigating SP-102 non-opioid therapy for lumbosacral radic...

Sorrento Therapeutics (SRNE) will host a R&D Day conference call and webcast on October 13, 2020 focusing on its multi-modal approach to COVID-19. Management will highlight strategic advancement, challenges, key pipeline updates and drivers of future growth in the COVID-19 space.R&D D...

SAN DIEGO, Oct. 04, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced it will host a R&D Day conference call and simultaneous webcast on October 13 th , 2020 focusing on its comprehensive multi-modal approach to COVID-19. ...

Zosano Pharma (ZSAN) -53% after FDA discipline review letter for Qtrypta.Selecta Biosciences (SELB) -44% after SEL-212 misses primary endpoint in mid-stage gout study.LogicBio Therapeutics (LOGC) -26% on launch of equity offering.ChinaNet Online Holdings (CNET) -...

At the beginning of this year, Sorrento Therapeutics (NASDAQ: SRNE) was focused on its pain management drug, resiniferatoxin, as well as its Dimeric Antigen Receptor-T (DAR-T) cell therapy targeting various blood cancers and solid tumors. But the biotech has made a major piv...